PRECISION? PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation

Paris (ots/PRNewswire) -

Boston Scientific Corporation has received CE Mark approval for
use of its PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System,
the world's first rechargeable SCS device, in peripheral nerve
stimulation for patients with chronic intractable pain of the trunk.
Peripheral nerve stimulation provides physicians and patients with an
additional treatment option for managing chronic intractable pain of
the trunk by stimulating peripheral nerves through a small surgically
implantable device.

"I am pleased to learn the PRECISION PLUS SCS System has received
CE Mark approval for peripheral nerve stimulation," said Dr. David
Abejón, consultant anaesthetist at Hospital Universitario Puerta de
Hierro Majadahonda, Madrid. "Based on my clinical experience and
research with peripheral nerve stimulation therapy to date, this
technique seems to be a promising treatment option in the field of
chronic intractable pain management."

Chronic intractable pain is continuous pain has lasted more than
six months. Living in constant pain for an extended period time can
have a devastating impact to quality of life for many patients.
Without relief, or the hope for relief, many patients lose the
ability to sleep, work, and function normally.

"Chronic pain affects nearly 95 million adults throughout
Europe," said Michael Onuscheck, senior vice president and president
of Europe, Middle East and Africa at Boston Scientific. "Expanding
our neuromodulation portfolio to include peripheral nerve stimulation
with the PRECISION PLUS SCS System continues our commitment to
providing physicians and patients with multiple treatment options for
the management of this debilitating condition."

About the PRECISION PLUSSCS System

The PRECISION PLUS SCS System was approved in the United States
in 2004 and received approval in Europe and Canada in 2005. The
system is the world's first rechargeable implantable pulse generator.
Today, more than 60,000 patients worldwide have been treated using
this system. When compared to non-rechargeable SCS systems,
rechargeable SCS systems may offer clinical benefits by extending
therapeutic longevity and therefore avoiding frequent replacement
surgeries and complications that may arise from repeated surgeries.

All cited trademarks are the property of their respective owners.
Caution: The law restricts these devices to sale by or on the order
of a physician. Inactions, contraindications, warnings, and
instructions for use can be found on the product labeling supplied
with each device. Information is for use only in countries with
applicable health authority product registrations.

About Boston Scientific Neuromodulation

Boston Scientific Neuromodulation is an innovation leader in
implantable pain management technology. Through its investments in
technology, clinical science, and world-class service, Boston
Scientific Neuromodulation is committed to making life smoother for
physicians and patients. For more information on the PRECISION PLUS
SCS System technology, visit http://www.ControlYourPain.com.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices that are used in a broad range of
interventional medical specialties. For more information, please
visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Forward-looking statements
may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and
estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding markets for our products, new product indications,
regulatory approvals, clinical trials, product performance and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that
may affect our future operations, see Part I, Item 1A - Risk Factors
in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II,
Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have
filed or will file hereafter. We disclaim any intention or obligation
to publicly update or revise any forward-looking statements to
reflect any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.

ots Originaltext: Boston Scientific Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Simonetta Balbi, +393387936422 (mobile), Media Relations
EMEA, Boston Scientific Corporation, Simonetta.balbi@bsci.com ;
Steven
Campanini, +1-508-652-5740 (office), Media Relations, Boston
Scientific
Corporation, steven.campanini@bsci.com ; Michael Campbell,
+1-508-650-8023
(office), Investor Relations, Boston Scientific Corporation,
investor_relations@bsci.com